DAVIS, Calif., Jan. 21, 2026 /PRNewswire/ — Antibodies Inc., a leading supplier of validated life science research reagents, today announced the availability ofDAVIS, Calif., Jan. 21, 2026 /PRNewswire/ — Antibodies Inc., a leading supplier of validated life science research reagents, today announced the availability of

Antibodies Inc. Launches Recombinant Guinea Pig RBPMS Antibody (OTI3B7-GP) for Reproducible Retinal Research

DAVIS, Calif., Jan. 21, 2026 /PRNewswire/ — Antibodies Inc., a leading supplier of validated life science research reagents, today announced the availability of its Recombinant Guinea Pig RBPMS Antibody (Clone OTI3B7-GP, Cat. No. 1834-RBPMS)—a next-generation antibody designed to deliver superior reproducibility, specificity, and performance in retinal ganglion cell (RGC) research.

Developed under the PhosphoSolutions brand, the recombinant Guinea Pig RBPMS Antibody continues a legacy of high-performance neuroscience reagents while benefiting from Antibodies Inc.’s expanded validation, manufacturing, and global distribution infrastructure. This new recombinant mAb replaces the formerly available guinea pig polyclonal RBPMS Antibody (Cat. No. 1832-RBPMS).

RBPMS (RNA Binding Protein with Multiple Splicing) has emerged as the gold-standard marker for identifying retinal ganglion cells, supporting accurate cell identification and quantification in vision and neurodegeneration research. While guinea pig polyclonal antibodies have historically been valuable for multiplex immunofluorescence, traditional formats are limited by lot-to-lot variability and finite supply.

Our Recombinant Guinea Pig RBPMS Antibody (OTI3B7-GP) addresses these limitations through recombinant engineering, eliminating lot-to-lot variability and supply constraints. The antibody combines the well-validated antigen-binding region of the OTI3B7 clone with a guinea pig IgG constant region, enabling efficient multiplexing alongside mouse and rabbit antibodies while delivering long-term consistency.

Key benefits include:

  • Recombinant RBPMS Antibody for retinal ganglion cell identification
  • Guinea Pig format for advanced multiplex immunolabeling
  • Clone OTI3B7-GP with defined amino acid sequence
  • Animal-free, serum-free production
  • Lot-to-lot reproducibility for longitudinal and multi-site studies

The antibody has been validated for immunohistochemistry (IHC) and Western blotting, providing clear and specific labeling of retinal ganglion cells in mammalian tissue samples.

The launch further reflects Antibodies Inc.’s commitment to supporting scientific discovery through a growing portfolio of specialized research brands.

Related Resources:
Explore the full PhosphoSolutions product line:
https://www.antibodiesinc.com/collections/phosphosolutions

Recombinant Guinea Pig RBPMS Antibody Product page:
https://www.antibodiesinc.com/products/anti-rbpms-antibody-recombinant-antibody-oti3b7-gp-1834-rbpms

Researchers seeking alternative host species can also access the Rabbit Polyclonal RBPMS Antibody:
https://www.antibodiesinc.com/products/anti-rbpms-antibody-1830-rbpms

Learn more about the Antibodies Inc. family of brands:
https://www.antibodiesinc.com/pages/our-brands

Available Now
The Recombinant Guinea Pig RBPMS Antibody (OTI3B7-GP, 1834-RBPMS) is available now through Antibodies Inc. and authorized global distributors.

About Antibodies Inc.
Antibodies Inc. provides researchers worldwide with rigorously validated antibodies, recombinant proteins, ELISA kits, and custom services. Through a growing portfolio of specialized brands—including PhosphoSolutions—Antibodies Inc. delivers reproducible tools that accelerate discovery across neuroscience, cell biology, and translational research.

Cision View original content:https://www.prnewswire.com/news-releases/antibodies-inc-launches-recombinant-guinea-pig-rbpms-antibody-oti3b7-gp-for-reproducible-retinal-research-302666278.html

SOURCE Antibodies Inc.

Market Opportunity
Graphite Logo
Graphite Price(GP)
$0.5381
$0.5381$0.5381
-7.95%
USD
Graphite (GP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

BFX Presale Raises $7.5M as Solana Holds $243 and Avalanche Eyes $1B Treasury — Best Cryptos to Buy in 2025

BFX Presale Raises $7.5M as Solana Holds $243 and Avalanche Eyes $1B Treasury — Best Cryptos to Buy in 2025

BFX presale hits $7.5M with tokens at $0.024 and 30% bonus code BLOCK30, while Solana holds $243 and Avalanche builds a $1B treasury to attract institutions.
Share
Blockchainreporter2025/09/18 01:07
Trading time: Tonight, the US GDP and the upcoming non-farm data will become the market focus. Institutions are bullish on BTC to $120,000 in the second quarter.

Trading time: Tonight, the US GDP and the upcoming non-farm data will become the market focus. Institutions are bullish on BTC to $120,000 in the second quarter.

Daily market key data review and trend analysis, produced by PANews.
Share
PANews2025/04/30 13:50
Franklin Templeton CEO Dismisses 50bps Rate Cut Ahead FOMC

Franklin Templeton CEO Dismisses 50bps Rate Cut Ahead FOMC

The post Franklin Templeton CEO Dismisses 50bps Rate Cut Ahead FOMC appeared on BitcoinEthereumNews.com. Franklin Templeton CEO Jenny Johnson has weighed in on whether the Federal Reserve should make a 25 basis points (bps) Fed rate cut or 50 bps cut. This comes ahead of the Fed decision today at today’s FOMC meeting, with the market pricing in a 25 bps cut. Bitcoin and the broader crypto market are currently trading flat ahead of the rate cut decision. Franklin Templeton CEO Weighs In On Potential FOMC Decision In a CNBC interview, Jenny Johnson said that she expects the Fed to make a 25 bps cut today instead of a 50 bps cut. She acknowledged the jobs data, which suggested that the labor market is weakening. However, she noted that this data is backward-looking, indicating that it doesn’t show the current state of the economy. She alluded to the wage growth, which she remarked is an indication of a robust labor market. She added that retail sales are up and that consumers are still spending, despite inflation being sticky at 3%, which makes a case for why the FOMC should opt against a 50-basis-point Fed rate cut. In line with this, the Franklin Templeton CEO said that she would go with a 25 bps rate cut if she were Jerome Powell. She remarked that the Fed still has the October and December FOMC meetings to make further cuts if the incoming data warrants it. Johnson also asserted that the data show a robust economy. However, she noted that there can’t be an argument for no Fed rate cut since Powell already signaled at Jackson Hole that they were likely to lower interest rates at this meeting due to concerns over a weakening labor market. Notably, her comment comes as experts argue for both sides on why the Fed should make a 25 bps cut or…
Share
BitcoinEthereumNews2025/09/18 00:36